Overview

The Pharmacokinetics of Single Dose Oral Tetrahydrocannabinol and Cannabidiol

Status:
Recruiting
Trial end date:
2023-12-31
Target enrollment:
Participant gender:
Summary
POT-GFR-PK is a single dose pharmacokinetic study oral tetrahydrocannabinol (THC) and cannabidiol (CBD) in healthy adult controls and individuals with chronic kidney disease including those treated with in-center hemodialysis.
Phase:
Phase 1
Details
Lead Sponsor:
McMaster University
Collaborator:
Center for Medicinal Cannabis Research
Treatments:
Cannabidiol
Dronabinol
Nabiximols